Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...

Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ETCompany ParticipantsSiting Li - IR DirectorStanley Peng - ...

Q1 2025 Earnings Call Transcript May 8, 2025 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome ...

Positive phase 3 results from the CAN-2409 clinical trial in intermediate-to-high risk localized prostate cancer have been ...

Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...

Additionally, prolonged inflammation changes the tissue microenvironment ... Head and neck cancers, particularly those affecting the oral cavity, pharynx, and esophagus, naturally show the ...

In fact, there are a number of entirely pragmatic reasons to conclude that prioritizing human factors is simply a good business strategy. In this article, we review the value of human factors ...

The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment ... from expected results. Other factors besides those we have listed could also ...

Welcome to Zymeworks first-quarter 2025 results conference call and webcast. (Operator Instructions) I would now like to turn the conference over to Shrinal Inamdar, Senior Director of Investor ...

Inovio Pharmaceuticals, Inc. ( NASDAQ: INO) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Jennie Willson - IR Jacqui Shea - President & CEO Mike Sumner - Chief Medical Officer Steve Egge - ...

Lauren Hirsch covers Wall Street for The Times, including M&A, executive changes, board strife and policy moves affecting business. Edmund Lee covers the media industry as it grapples with changes ...